Octreotide Acetate Injection 500 mcg/mL, 10 x 1 mL Single-Dose Unit-of-Use Syringes, For Subcutaneous or Intravenous Use, Rx Only, Manufactured for: Mylan Institutional LLC, Morgantown, WV 26505 U.S.A., Made in Italy, NDC: 67457-246-00 (syringe), 67457-246-01 (carton).
Published November 16, 2022 · Recall initiated: October 7, 2022
Summary
FDA records drug Class I recall D-0058-2023, published November 16, 2022 and initiated October 7, 2022. Recalling firm: Viatris Inc; Status: Terminated; Reported quantity: 22400 syringes; Lot: Lot #: AJ21002, Exp. 03/2024. Class I means a reasonable probability of serious adverse health consequences or death.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Presence of Particulate Matter: Product complaint for the presence of glass particles in a syringe.
What to do
Voluntary: Firm initiated · Letter
Get an email if OCTREOTIDE ACETATE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- OCTREOTIDE ACETATE
- Manufacturer
- Viatris Inc
- Distributor
- Nationwide in the USA
- Lot
- Lot #: AJ21002, Exp. 03/2024
- Risk classification
- Class I
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, In Single-Dose kitsMay 13, 2026
- FDAOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg, Single-dose 8 mL vial inApril 1, 2026
- FDAOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 20 mg, Single-dose 8 mL vial inApril 1, 2026
- FDAOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, Single-dose 8 mL vial inApril 1, 2026
- FDA2 oz. units of Pomegranate Fruit Roll Ups in boxes of 24, sold as individual units. Ingredients: Apple,November 16, 2022
- FDABD Multitest 6-Color TBNK with optional BD Trucount Tubes (Cat. No. 662995), for use with BD FACSLyric, BDNovember 9, 2022
Questions about this recall
Was Octreotide Acetate Injection 500 mcg/mL, 10 x 1 mL Single-Dose Unit-of-Use Syringes, For Subcutaneous or Intravenous Use, Rx Only, Manufactured for: Mylan Institutional LLC, Morgantown, WV 26505 U.S.A., Made in Italy, NDC: 67457-246-00 (syringe), 67457-246-01 (carton). recalled?
Yes. FDA published recall D-0058-2023 on November 16, 2022. Reported hazard: Presence of Particulate Matter: Product complaint for the presence of glass particles in a syringe.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: OCTREOTIDE ACETATE.